BioSpace News Archive

Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, announces that following the Company’s voluntary delisting of the Company’s American Depositary Shares representing its ordinary shares from Nasdaq Global Select Market has become effective on March 31, 2022.

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, provided a business update and announced financial results for the fourth quarter and year ended December 31, 2021.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in March 2022.

SELLAS Life Sciences Group, Inc. announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offering price of $5.40 per share and accompanying warrant.

On March 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer.

CTI BioPharma Corp. reported its financial results for the fourth quarter and full year ended December 31, 2021.

INVO Bioscience, Inc. announced financial results for the year ended December 31, 2021, and provided a business update.

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.

Silverback Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021.